Vor Bio, a clinical-stage cell and genome engineering company, has appointed Mr. Erez Kalir to its Board of Directors, creating a new seat following a recent private investment in public equity ...

Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchase agreement for a private ...

Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical ...